Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-CTLA-4 therapy for malignant mesothelioma.
Guazzelli A, Bakker E, Krstic-Demonacos M, Lisanti MP, Sotgia F, Mutti L. Guazzelli A, et al. Among authors: mutti l. Immunotherapy. 2017 Mar;9(3):273-280. doi: 10.2217/imt-2016-0123. Immunotherapy. 2017. PMID: 28231719 Free article. Review.
The role of microenvironment and immunity in drug response in leukemia.
Bakker E, Qattan M, Mutti L, Demonacos C, Krstic-Demonacos M. Bakker E, et al. Among authors: mutti l. Biochim Biophys Acta. 2016 Mar;1863(3):414-426. doi: 10.1016/j.bbamcr.2015.08.003. Epub 2015 Aug 6. Biochim Biophys Acta. 2016. PMID: 26255027 Free article. Review.
Tremelimumab for the treatment of malignant mesothelioma.
Guazzelli A, Hussain M, Krstic-Demonacos M, Mutti L. Guazzelli A, et al. Among authors: mutti l. Expert Opin Biol Ther. 2015;15(12):1819-29. doi: 10.1517/14712598.2015.1116515. Expert Opin Biol Ther. 2015. PMID: 26560442 Review.
Targeting hypoxic response for cancer therapy.
Paolicchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, Mutti L, Landi S. Paolicchi E, et al. Among authors: mutti l. Oncotarget. 2016 Mar 22;7(12):13464-78. doi: 10.18632/oncotarget.7229. Oncotarget. 2016. PMID: 26859576 Free PMC article. Review.
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines.
Melaiu O, Catalano C, De Santi C, Cipollini M, Figlioli G, Pellè L, Barone E, Evangelista M, Guazzelli A, Boldrini L, Sensi E, Bonotti A, Foddis R, Cristaudo A, Mutti L, Fontanini G, Gemignani F, Landi S. Melaiu O, et al. Among authors: mutti l. Genes Cancer. 2017 Jan;8(1-2):438-452. doi: 10.18632/genesandcancer.129. Genes Cancer. 2017. PMID: 28435517 Free PMC article.
Immunotherapy advances for mesothelioma treatment.
Bakker E, Guazzelli A, Ashtiani F, Demonacos C, Krstic-Demonacos M, Mutti L. Bakker E, et al. Among authors: mutti l. Expert Rev Anticancer Ther. 2017 Sep;17(9):799-814. doi: 10.1080/14737140.2017.1358091. Epub 2017 Jul 31. Expert Rev Anticancer Ther. 2017. PMID: 28724330 Free article. Review.
178 results